It is intriguing that these in vitro results correlate with the apparent superior clinical benefit of a phosphodiesterase 4B inhibitor (which enhances intracellular cAMP levels) in patients with IPF compared with pirfenidone and nintedanib in a recent phase II clinical trial (78). Here, PDE4B is linked to idiopathic pulmonary fibrosis.